PDX Pharmaceuticals, LLC has been selected to participate in the NIH SBIR/STTR Commercialization Accelerator Program (CAP) program.

PDX Pharmaceuticals, LLC has been selected to participate as a member of the 2017-2018 Cohort of the NIH SBIR/STTR Commercialization Accelerator Program (CAP) for Phase II awardees. “NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in measurable gains and accomplishments by participating companies. Offered since 2004 to address the commercialization objectives of companies across the spectrum of experience and stage, 900+ companies have participated in the CAP. It is open only to HHS/NIH SBIR/STTR Phase II awardees, and 80 slots are available each year. The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.”